Journal of Clinical Microbiology · 2004 · 66 citations · 18 references
Veterinary MedicineInfectious DiseasesMolecular BiologyAntimicrobial ResistanceDiagnostic MicrobiologyMolecular DiagnosticsAntibiotic ResistanceMycobacterial DiagnosticsPathogen DetectionTuberculosis DiagnosisTuberculosis Diagnostic TestingDrug Resistance TestingIsoniazid Resistance TestingMolecular BeaconsPhenotypic Drug Susceptibility TestingRapid Detection AssaysRapid Molecular DiagnosticsResistance PrevalenceTuberculosis Molecular Testing
The slow-growing nature of Mycobacterium tuberculosis complex hinders the improvement of turnaround time for phenotypic drug susceptibility testing. We designed a set of molecular beacons for the detection of isoniazid and rifampin resistance mutations in M. tuberculosis complex organisms from cultures or from N-acetyl-l-cysteine-NaOH-treated, smear-positive specimens. The performance of the molecular beacons was characterized by studying a total of 196 clinical isolates (127 drug-resistant isolates and 69 drug-susceptible isolates). For detection of isoniazid resistance, the sensitivity and specificity of the assay were 82.7 and 100%, and the positive predictive value (PPV) and negative predictive value (NPV) at a resistance prevalence of 10% were 100 and 98.11%, respectively. For detection of rifampin resistance, the sensitivity and specificity of the assay were 97.5 and 100%, and the PPV and NPV at a resistance prevalence of 2.0% were 100 and 99.95%, respectively.
18
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Amalio Telenti, Paul Imboden, Federica Marchesi et al. · The Lancet · 1993 · 1.3K citations
Multicolor molecular beacons for allele discrimination
Sanjay Tyagi, Diana P. Bratu, Fred Russell Kramer · Nature Biotechnology · 1998 · 1.3K citations